Table 6

APL evolution in children during follow-up with at least 1 dosage before and after 6 months

Non-persistent APLPersistent APLDe novo APL
Lupus anticoagulant (n=24)1 (4%)1 (4%)1 (4%)
Anticardiolipin IgG (n=54)9 (17%)5 (9%)5 (9%)
Anticardiolipin IgM (n=53)1 (2%)
Anti-β2GPI IgG (n=49)9 (18%)4 (8%)8 (16%)
Anti-β2GPI IgM (n=48)1 (2%)1 (2%)
  • This table represents APL in children who have at least two APL determinations before and after 6 months in order to discriminate the passive transplacental transfer from APL synthesis de novo, as well as to represent the persistent APL.

  • Anti-β2GPI; anti-β2 glycoprotein-I antibodies; APL, antiphospholipid antibodies.